Impact of Docosahexaenoic Acid Therapy on Subgingival Plaque Microbiota

Journal of Periodontology
Asghar Z NaqviJ Max Goodson

Abstract

Oral docosahexaenoic acid (DHA) + aspirin therapy has been shown to reduce periodontal probing depth (PD) and local inflammatory mediators in gingival crevicular fluid (GCF) among patients with untreated chronic periodontal disease. Whether DHA + aspirin therapy influences specific bacterial burden in this setting is unknown. Thus, the aim of this study is to evaluate the impact of DHA with low-dose aspirin therapy on periodontal bacterial profile in patients with periodontitis. Fifty-five adults with moderate-to-severe periodontitis were enrolled in a randomized, 3-month double-masked, placebo-controlled trial of daily 2 g DHA or placebo capsules enriched with 81 mg aspirin; 46 enrollees completed the trial. In addition to clinical measurements and GCF sampling, subgingival plaque samples were collected from four posterior sites in all participants and analyzed by the checkerboard DNA-DNA hybridization technique. Presence of 40 periodontal bacterial species at baseline and 3 months was semiquantitatively estimated. Despite broad improvements in clinical parameters, total bacteria and individual species counts in dental plaque did not differ significantly between baseline and 3 months in either group (P >0.1 for all). A modest ...Continue Reading

Associated Clinical Trials

Nov 6, 2013·Kenneth Mukamal, Kenneth Mukamal

References

May 1, 1997·Journal of Clinical Periodontology·A D HaffajeeS S Socransky
Jan 27, 1998·Journal of Clinical Periodontology·P CampanD Duran
Mar 12, 1998·Journal of Clinical Periodontology·S S SocranskyR L Kent
Jun 23, 2000·Annals of Periodontology·G C Armitage
Apr 23, 2002·Journal of Clinical Periodontology·Jörg EberhardSøren Jepsen
Feb 20, 2003·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Elliot D RosensteinGregory Kazandjian
Dec 1, 1963·Acta Odontologica Scandinavica·H LOE, J SILNESS
Sep 23, 2003·Infection and Immunity·Ashish JainThomas E Van Dyke
Dec 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Charles N SerhanThomas E Van Dyke
Dec 22, 2005·Nature Immunology·Charles N Serhan, John Savill
Dec 24, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·H HasturkT E Van Dyke
Dec 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bruce D LevyCharles N Serhan
Nov 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hatice HasturkThomas E Van Dyke
Apr 26, 2008·Nature Reviews. Immunology·Charles N SerhanThomas E Van Dyke
Nov 3, 2010·Journal of the American Dietetic Association·Asghar Z NaqviKenneth J Mukamal
Nov 13, 2010·Circulation Research·Matthew Spite, Charles N Serhan
Sep 4, 2012·Nature Reviews. Microbiology·George HajishengallisMichael A Curtis
Sep 12, 2012·Immunobiology·George Hajishengallis, John D Lambris
Apr 12, 2013·Periodontology 2000·P Mark Bartold, Thomas E Van Dyke
Dec 19, 2013·Lasers in Medical Science·Nikolaos S SoukosJ Max Goodson
Jun 28, 2014·Journal of Dental Research·A Z NaqviK J Mukamal

❮ Previous
Next ❯

Citations

Aug 10, 2020·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Duo-Na XiaGang Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.